Philip Morris International (NYSE:PM) Stock Analysis: FDA Win Fuels Smoke-Free Growth

• Philip Morris International (NYSE:PM) is strategically shifting its business focus towards smoke-free products like IQOS and Zyn, moving away from traditional cigarettes.
• The U.S. FDA's authorization of Zyn nicotine pouches with a "modified-risk" claim provides a significant marketing advantage, allowing the company to highlight reduced health risks.
• This strategic pivot is driving strong financial performance, with smoke-free products contributing over 43% of net revenues and robust operating cash flow, despite a "Neutral" rating from UBS due to existing debt and negative shareholders' equity.

Philip Morris International (NYSE:PM) is a global tobacco company known for brands like Marlboro. It is now shifting its focus toward smoke-free products, such as its IQOS heated tobacco devices and Zyn nicotine pouches. The company's stock is currently priced at $177.69, giving it a market capitalization of approximately $276.94 billion.

On July 2, 2026, the financial services firm UBS raised its price target on Philip Morris International to $182.00 from $168.00. This update follows a significant regulatory win for the company. The U.S. Food and Drug Administration (FDA) has authorized Philip Morris International to market its Zyn nicotine pouches as a less harmful alternative to cigarettes.

As highlighted by CNBC, this decision allows 20 Zyn products to carry a "modified-risk" claim. This means the company can advertise that switching from cigarettes to Zyn lowers the risk of mouth cancer, heart disease, and lung cancer, among other diseases. This provides a major marketing advantage as traditional cigarette sales decline.

This strategic pivot is reflected in the company's finances. Smoke-free products now account for over 43% of Philip Morris International's net revenues. The company also shows strong cash generation, with an operating cash flow of about $12.23 billion in 2025. This figure is expected to grow to around $13.50 billion in 2026, easily covering dividend payments.

Despite these positive developments, UBS maintained its Neutral rating on the stock. This "hold" recommendation may reflect that the stock's price of $177.69 is already near the new $182.00 target. The company also has a negative shareholders' equity of $7.30 billion after acquiring Swedish Match, and it is working to reduce its debt.